Dimethylbarbiturate

Dimethylbarbiturate

SCHEMBL296700

CC1(C)C(=O)NC(=O)NC1=O

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.48
MMP9 P14780 4/20 0.44
MMP2 P08253 3/20 0.44
PDK2 Q15119 3/20 0.39
PDK4 Q16654 2/20 0.39
KDM4E B2RXH2 3/20 0.37
MAPT P10636 3/20 0.37
RECQL P46063 2/20 0.37
BLM P54132 2/20 0.37
OGT O15294 1/20 0.37
USP2 O75604 1/20 0.37
MMP13 P45452 2/20 0.37
TP53 P04637 2/20 0.36
ALDH1A1 P00352 2/20 0.34
CYP3A4 P08684 2/20 0.34
GABRB3 P28472 1/20 0.34
OPRD1 P41143 1/20 0.34
GABRA2 P47869 1/20 0.34
GABRB2 P47870 1/20 0.34
MMP8 P22894 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dimethylbarbiturate SCHEMBL31271990 0.97 LMNA (0.46) LMNAMMP9MMP2PDK2PDK4
SCHEMBL11278121 0.73 LMNA (0.43) LMNAMMP9MMP2KDM4EMAPT
SCHEMBL8991935 0.73 LMNA (0.39) LMNAPDK2PDK4KDM4EMAPT
SCHEMBL12965826 0.71 PDK2 (0.50) PDK2PDK4KDM4EMAPTRECQL
SCHEMBL3974105 0.69 LMNA (0.46) LMNAMMP9MMP2KDM4EMAPT
SCHEMBL11173511 0.69 LMNA (0.40) LMNAMMP9MMP2KDM4EMAPT
SCHEMBL8348835 0.69 LMNA (0.59) LMNAMMP9MMP2KDM4EMMP13
SCHEMBL17294203 0.67 MMP9 (0.39) LMNAMMP9MMP2MAPTMMP13
SCHEMBL11818576 0.67 LMNA (0.39) LMNAMMP9MMP2MMP13TP53
SCHEMBL9591821 0.67 PDK2 (0.71) LMNAMMP9MMP2PDK2PDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 477 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115452747-B Method for detecting activation degree of cyanogen bromide activated polysaccharide 艾美探索者生命科学研发有限公司 2025-05-20 CN claimed
CN-118518606-A Method for detecting carbodiimide content 爱美客技术发展股份有限公司 2024-08-20 CN claimed
CN-116879198-A Method for detecting EDAC residual quantity in crosslinked recombinant collagen anti-blocking film 浙江诸暨聚源生物技术有限公司 2023-10-13 CN claimed
WO-2023111869-A1 METHOD FOR SYNTHESIZING AN ANTI-CANCER COMPOUND THROUGH A ONE-POT REACTION BATOOIE NASIM (IR) 2023-06-22 WO claimed
EP-3454981-B1 PALLADIUM CATALYSTS WITH IMPROVED PERFORMANCE IN BIOLOGICAL ENVIRONMENTS PROMEGA CORP (US) 2021-03-03 EP claimed
US-10882035-B2 Palladium catalysts with improved performance in biological environments PROMEGA CORPORATION (US) 2021-01-05 US claimed
EP-3454981-A1 PALLADIUM CATALYSTS WITH IMPROVED PERFORMANCE IN BIOLOGICAL ENVIRONMENTS Promega Corporation (US) 2019-03-20 EP claimed
WO-2017196985-A9 PALLADIUM CATALYSTS WITH IMPROVED PERFORMANCE IN BIOLOGICAL ENVIRONMENTS PROMEGA CORPORATION (US) 2018-12-13 WO claimed
US-20180029028-A1 PALLADIUM CATALYSTS WITH IMPROVED PERFORMANCE IN BIOLOGICAL ENVIRONMENTS JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2018-02-01 US claimed
WO-2017196985-A1 PALLADIUM CATALYSTS WITH IMPROVED PERFORMANCE IN BIOLOGICAL ENVIRONMENTS PROMEGA CORPORATION (US) 2017-11-16 WO claimed
US-20150111038-A1 AMIDES OF 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AND THEIR SALTS GLENMARK PHARMACEUTICALS S.A. (CH) 2015-04-23 US claimed
EP-2858999-A2 AMIDES OF 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AND THEIR SALTS Glenmark Pharmaceuticals S.A. (CH) 2015-04-15 EP claimed
WO-2013183035-A2 AMIDES OF 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AND THEIR SALTS GLENMARK PHARMACEUTICALS S.A. (CH) 2013-12-12 WO claimed
US-20130165658-A1 PROCESS FOR THE PREPARATION OF IODIDES TECHNION R&D FOUNDATION LTD. (IL) 2013-06-27 US claimed
WO-2011154953-A1 PROCESS FOR THE PREPARATION OF IODIDES TECHNION R&D FOUNDATION LTD. (IL) 2011-12-15 WO claimed
US-7863264-B2 Stabilised compositions having antibacterial activity COLOPLAST A/S (DK) 2011-01-04 US claimed
WO-2010068789-A1 POLYETHYLENE GLYCOL-COATED SODIUM CARBONATE AS A PHARMACEUTICAL EXCIPIENT AND COMPOSITIONS PRODUCED FROM THE SAME TRANSCEPT PHARMACEUTICALS, INC. (US) 2010-06-17 WO claimed
EP-0566289-B1 Analysis of hemoglobin variants by capillary electrophoresis BECKMAN INSTRUMENTS INC (US) 1996-02-07 EP claimed
EP-0566289-A1 Analysis of hemoglobin variants by capillary electrophoresis BECKMAN INSTRUMENTS, INC. (US) 1993-10-20 EP claimed
US-5202006-A Using barbituric acid buffer BECKMAN INSTRUMENTS, INC. (US) 1993-04-13 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180029028-A1 PALLADIUM CATALYSTS WITH IMPROVED PERFORMANCE IN BIOLOGICAL ENVIRONMENTS PDCD2L, PDCD1, PDCD1LG2 LMNA 4170/4885MMP9 1784/4885MMP2 1731/4885
US-10882035-B2 Palladium catalysts with improved performance in biological environments PDCD2L, PDCD1, PDCD1LG2 LMNA 4170/4885MMP9 1784/4885MMP2 1731/4885
US-20150111038-A1 AMIDES OF 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AND THEIR SALTS AADAC, ABL2, ABL1 LMNA 4559/4885MMP9 4602/4885MMP2 4372/4885
US-20130165658-A1 PROCESS FOR THE PREPARATION OF IODIDES NISCH, TPO, HDHD5 LMNA 3825/4885MMP9 4251/4885MMP2 2914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.